Biovac Opens Advanced Vaccine Development Laboratory in Cape Town to Strengthen Africa's Manufacturing Independence
Key Insights
Biovac (search) launched a state-of-the-art product development laboratory in Cape Town on November 6, 2025, backed by the Gates Foundation (search) to advance Africa's vaccine manufacturing capabilities.
The facility features advanced mRNA technology and will enable full-spectrum vaccine development from early research through manufacturing, targeting diseases prevalent in Africa including HIV/AIDS (search), tuberculosis (search), and malaria (search).
The laboratory supports the African Union (search)'s goal to produce 60% of vaccines locally by 2040, up from the current 1%, addressing supply vulnerabilities exposed during the COVID-19 (search) pandemic.
South African biopharmaceutical company Biovac (search) opened a cutting-edge product development laboratory in Cape Town on Thursday, November 6, 2025, marking a significant milestone in Africa's quest for vaccine manufacturing independence. The facility, backed by the Gates Foundation (search), represents a strategic shift from the continent's historical reliance on imported vaccines to developing homegrown solutions for diseases prevalent across Africa.
The new laboratory enables Biovac (search) to move beyond its current "fill and finish" operations to full end-to-end vaccine production, incorporating advanced technologies including messenger RNA (mRNA) platforms. This expansion addresses critical vulnerabilities exposed during the COVID-19 (search) pandemic, when African countries faced severe delays and shortages while wealthier nations secured bulk vaccine supplies through advance purchase agreements.
Advanced Technology Platform for African Diseases
The Cape Town facility houses specialized infrastructure for mRNA drug substance development, screening, evaluation, and manufacturing. The laboratory includes a dedicated suite for formulating nanoparticles that safely encapsulate and protect mRNA, along with areas for bacterial and cell culture, cell bank storage, and handling of sensitive medical materials.
The facility will focus on developing vaccines for diseases particularly affecting African populations, including HIV/AIDS (search), tuberculosis (search), malaria (search), and emerging viral threats like Ebola (search) and COVID-19 (search) variants. "This is a major milestone for Biovac (search) and for African vaccines and vaccine innovation," said Biovac Chief Executive Morena Makhoana, emphasizing that the lab will ensure "that Africa is not left behind in responding to current and future vaccine-preventable diseases."
Addressing Continental Supply Vulnerabilities
Africa's vaccine dependency has left the continent vulnerable to supply disruptions and global market pressures. Currently, approximately 1% of vaccines used on the continent are produced locally, according to Biovac (search) data. The African Union (search) has set an ambitious target to increase local vaccine production to 60% by 2040, and the new laboratory is expected to help close this significant gap.
Biovac (search) currently supplies vaccines for South Africa's childhood immunization programme, treating diseases including tuberculosis (search), tetanus (search), diphtheria (search), poliomyelitis (search), haemophilus influenzae, and hepatitis B (search). During the pandemic, the company struck agreements with Pfizer and BioNTech to produce vaccines for the African Union (search), demonstrating its capacity for international partnerships.
Strategic Government and Foundation Support
The laboratory launch was headlined by Dr. Nomalungelo Gina, Deputy Minister of Science, Technology and Innovation, underscoring the South African government's strategic commitment to local pharmaceutical manufacturing and health sovereignty. The Department of Science, Technology and Innovation stated that "this milestone supports the government's broader goal of strengthening local pharmaceutical manufacturing and ensuring that South Africa and the continent are better prepared to respond to health emergencies with homegrown solutions."
Mark Suzman, CEO of the Gates Foundation (search), attended the opening, highlighting the Foundation's ongoing commitment to equitable vaccine access and global health innovation. "For millions of people across the continent, (the lab) brings the promise of faster, more reliable access to lifesaving vaccines developed and produced in Africa, for Africa," Suzman said.
Innovation and Intellectual Property Development
The laboratory's design allows multiple products to be developed simultaneously, fostering innovation and intellectual property creation specifically for vaccines targeting diseases prevalent in Africa. This capability represents a fundamental shift from dependency on foreign pharmaceutical imports to building autonomous research and development ecosystems for African scientists and researchers.
The facility is expected to accelerate the development of regionally relevant vaccines, enhance clinical trial capabilities, and expand product pipeline development. Biovac (search) has received sustained support from the South African government, the Gates Foundation (search), and the Industrial Development Corporation, positioning the company as a pillar in Africa's immunization strategy through the Expanded Programme on Immunisation serving millions of infants and children across public and private healthcare sectors.